We are thrilled to welcome Rita & Danny to our Residency Program @TuftsMCRadOnc, allied with @BIDMC and @UMass!🎉 #Match2026 #RadOnc #ResidencyMatch

FANSS study: low-dose CT screening feasible, valuable for lung cancer screening for Asian non-smoking women

Supports expansion of guidelines to include high-risk populations

Presenter: @elaineshummd.bsky.social
Discussant: David R. Baldwin, MD

ascopost.com/news/october...

Fumiko Ladd Chino: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens - OncoDaily Fumiko Ladd Chino: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens / Amy Caramore, Amy L. Tin, Andrew J. Vickers,

Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens - Fumiko Ladd Chino

@fumikochino.bsky.social @chaewonhwangmd.bsky.social @jbudhu.bsky.social @bthomphd.bsky.social

oncodaily.com/voices/fumik...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedOnc #MedNews

Additionally, there was no correlation between level of #financialtoxicity and the type of planned #radiationtherapy, CyberKnife SBRT, or hypofractionated/conventional EBRT. Important to note that this was baseline survey prior to start of RT! Longitudinal data is being collected

Despite our prostate cancer patients being more likely to report low #financialtoxicity, those with high FT were still more likely to engage in cost-coping mechanisms like delaying or avoiding medical care and reducing spending on leisure, which can negatively impact outcomes and QoL

meetings.asco.org/abstracts-pr...

Excited to share our findings regarding #financialtoxicity of our patients with prostate cancer presenting for #radiationtherapy @bidmc-cancercenter.bsky.social @bidmcreseach.bsky.social ! And excited to learn more about delivery of quality care and barriers to cancer care at #ASCOQLTY25!

#ASTRO25 ! Thank you for the opportunity to present our work on #financialtoxicity in patients undergoing radiation treatment, specifically on baseline FT and cost-coping mechanisms. Stay tuned for #ASCOQLTY25 for subanalysis on our prostate cancer patient cohort! #radonc

Abstract titles for #ASCOQLTY25 are now live! Get a first look at the solution-oriented cancer research that will be presented at the symposium: asco.org/qcs-abstracts

If you haven’t yet confirmed your attendance, registration is still open: brnw.ch/21wVpzR

More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8
#ASCODailyNews #GICSM

Day 3 of #ASCO25 ! Honored to be presenting on how social determinants of health affect immunotherapy use in Stage III NSCLC patients after definitive chemoradiation @ascocancer.bsky.social @bidmcreseach.bsky.social @bidmc-cancercenter.bsky.social #TuftsMedicalCenter

Day 2 of #ASCO25! Exciting new frontiers in harnessing power of AI to better cancer care! As Dr. Robin Zon, President of @ascocancer.bsky.social, & Ms. Ruth Porat, President & CIO of Google and Alphabet, mentioned, AI is augmenting human capabilities, and it's about using it as an agent for change

Federal Funding for Cancer Research As Congress negotiates Fiscal Year 2025 appropriations bills, urge them to make cancer research a top priority.

@cliffordhudis.bsky.social at #ASCO25: ~40% cut to NCI budget in Admin's '26 proposal. We are in a tragic paradox: remarkable science & historic cuts to resources needed to turn these opps into hope for millions of pts. Our advocacy, is more important than ever ➡️ brnw.ch/21wT3U4

Thrilled to be at #ASCO25 ! Excited to witness and be a part of the forefront of cancer research! And honored to present research @ascocancer.bsky.social

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH

Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...

Incredible findings of Phase II study where px with stage I, II, or III dMMR solid tumors that were amenable to curative-intent surgery were treated with neoaduvant dostarlimab for 6 months:
➡️ recurrence-free survival at 2 years was 92%

#AACR25 #Oncology #research

www.nejm.org/doi/full/10....

📣 Phase III KEYNOTE-689 trial: Addition of perioperative Pembrolizumab to standard of care tx for locally advanced HNSCC significantly improved event free survival and major pathologic response. Presented
@ #AACR 2025 meeting: www.aacr.org/about-the-aa...

#Oncology #research #radonc

How To Write a Response to Reviewers

Helpful guide to responding to reviewers, when submitting research to journals: www.sciencedirect.com/science/arti...

#meded #oncology #research #radonc

Excited to be presenting our research #ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT:
meetings.asco.org/abstracts-pr...
@bidmcreseach.bsky.social
#TuftsMedicine

📣 Big shoutout to our faculty at #TuftsMedicine & @bidmc-cancercenter.bsky.social radiation oncology residency, Dr. Jang and Dr. Huber, for being speaker and moderator at this year's @astro-org.bsky.social Annual RefresherCourse! Thank you for all that you do for us and for the #radonc community!

Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 ...

"Deintensification of chemoradiation treatments for HPV-associated oropharyngeal cancers is of very high interest to patients and researchers, but our study makes clear that these approaches should remain experimental.”
— SUE YOM, MD, PhD, FASTRO. ascopost.com/news/april-2...
@ascopost.bsky.social

We had a record number of abstracts submitted for #ACRO2025! 👏 Impressive work by all our residents who presented at #ACROinVegas! See all the photos here: www.facebook.com/media/set?va...